ReviewJournal of healthcare leadership2025
Artificial Intelligence in Cancer Oncology Through Comprehensive Bibliometric Mapping of Global Trends Impact and Conceptual Structures.
Review in Journal of healthcare leadership, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence in pharmacy and pharmaceutical sciences: Research output, trends, and thematic priorities - A descriptive analysis of web of science-indexed publications (2010-2025).Exploratory research in clinical and social pharmacy · 2026Article
- Evolution of artificial intelligence in breast cancer pathology: a bibliometric analysis.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of artificial intelligence, particularly deep learning, has transformed cancer oncology through more precise diagnostics, personalized therapies, and improved clinical decision-making. This study conducts a bibliometric mapping to capture global research trends, intellectual influence, and conceptual structures in cancer oncology and deep learning. A total of 19,627 peer-reviewed articles published between 2022 and 2025 were analyzed, retrieved from an initial dataset of 34,218 documents. Using Correspondence Analysis (CA) and Multiple Correspondence Analysis (MCA) in RStudio, we evaluated both Author Keywords and Keyword Plus. The results highlight dominant themes, including multimodal learning and radiogenomics, while also uncovering emerging directions such as transformer-based models, federated learning for cross-institutional data, and the ethical dimensions of explainable AI in clinical workflows. MCA on Keyword Plus provided stronger explanatory power (80.01% and 8.76% for the first two dimensions) compared to CA on Author Keywords (5.27% and 3.73%). This mapping reveals critical gaps-such as limited participation from low- and middle-income countries, lack of standardized datasets, and insufficient multidisciplinary collaboration. By identifying these challenges and opportunities, the study provides actionable insights for researchers, policymakers, and clinicians to advance inclusive and ethically responsible AI-driven cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.